ubx0101
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 16, 2018 (NCT03513016)
Timeline
Indications
Studied for
Mechanism of action
- Cellular tumor antigen p53ANTAGONIST
TP53 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04229225 | Phase 1 | Jan 31, 2020 | UNITY Biotechnology |
| NCT04129944 | Phase 2 | Nov 30, 2019 | UNITY Biotechnology |
| NCT03513016 | Phase 1 | May 16, 2018 | UNITY Biotechnology |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| UNITY Biotechnology | For profit | 3 | 3 | 2 | 2018 |
1 organizations
Page 1 / 1